A Phase 3 Clinical Study for People With Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis

STUDY GOALS:

  • To find out if AL amyloidosis patients treated with MLN9708 plus dexamethasone respond better than patients treated with other chemotherapies that physicians use
  • To determine if MLN9708 plus dexamethasone can change the chance that amyloidosis will cause the heart and/or kidneys to begin to work poorly, leading to hospitalization or death

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Have relapsed or refractory AL amyloidosis
  • Have received 1 or 2 prior therapies for AL amyloidosis
  • Are 18 years of age or older
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT
AL AMYLOIDOSIS

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
We want to answer your questions about this study, but our office is closed now.
Would you like us to call you back?
1-888-559-7901
Monday–Friday 9am–7pm ET